Drug
Elinzanetant Treatment A
Elinzanetant Treatment A: highest development phase Phase 1, developed by Bayer. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Bayer
Trials
| Drug | Phase | Indication |
|---|---|---|
| Elinzanetant (BAY 3427080) treatment A NCT07762287 | Phase 1 | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women |
Latest
No recent events.
Follow Elinzanetant Treatment A on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.